Skip to main content
Mary Beth Scholand
( out of 501 reviews )

Mary Beth Scholand, MD

Languages spoken: English

Clinical Locations

Farmington Health Center

Farmington
801-213-3200

South Jordan Health Center

South Jordan
801-213-4500

Sugar House Health Center

Salt Lake City
801-581-2000

University of Utah Hospital

Pulmonary, Clinic 3
Salt Lake City
801-581-7806
  • Dr. Mary Beth Scholand, MD is an associate professor in Pulmonary Medicine. Her research and clinical interest is Interstitial Lung Disease. This interest encompasses Idiopathic Pulmonary Fibrosis, Autoimmune Lung Diseases and Sarcoidosis. She is the Director of the Interstitial Lung Disease Clinic. She runs clinical trials focused on a cure for Idiopathic Pulmonary Fibrosis. In addition, her research focuses on phenotypic factors and genetic factors associated with Chronic Obstructive Pulmonary Diseases and Interstitial Lung Diseases.

    Board Certification

    American Board of Internal Medicine (Sub: Pulmonary Disease)
    National Board of Medical Examiners

    Patient Rating

    4.9 /5
    ( out of 501 reviews )

    The patient rating score is an average of all responses on our patient experience survey. The rating averages scores for all questions about care from our providers.

    The scale on which responses are measured is 1 to 5 with 5 being the best score.

    Patient Comments

    Patient comments are gathered from our patient experience survey and displayed in their entirety. For the convenience of our visitors, some patient comments have been translated from their original language into English while preserving their original meaning as accurately as possible. Patients are de-identified for confidentiality and patient privacy.

    March 30, 2025
    FARMINGTON HEALTH CENTER

    She is very concerned with how I am doing and keeps track of this.

    March 30, 2025
    FARMINGTON HEALTH CENTER

    Dr Scholand is fantastic

    March 27, 2025
    SUGAR HOUSE HEALTH CENTER

    Excellent care in all ways!

    March 22, 2025
    UNIVERSITY HOSPITAL

    Dr. Sholand cares about her patients and takes care to keep keep them updsted with the latest in treatments.

    March 21, 2025
    SUGAR HOUSE HEALTH CENTER

    She's great. She listens!

    March 21, 2025
    UNIVERSITY HOSPITAL

    Dr. Scholand is an excellent pulmonologist. Her team responds quickly to my lung disease needs. She works with several clinical trials to research the processes that will benefit my health.

    March 20, 2025
    SUGAR HOUSE HEALTH CENTER

    I would recommend Mary Beth Scholand to anyone facing a lung disease.

    March 19, 2025
    SUGAR HOUSE HEALTH CENTER

    Dr. Scholand is the best. I completely trust her with my care. Highly trust and recommend.

    March 14, 2025
    UNIVERSITY HOSPITAL

    Dr Scholand is very thorough and professional. She is also very kind. So lucky to have her oversee my health.

  • Dr. Mary Beth Scholand, MD is an associate professor in Pulmonary Medicine. Her research and clinical interest is Interstitial Lung Disease. This interest encompasses Idiopathic Pulmonary Fibrosis, Autoimmune Lung Diseases and Sarcoidosis. She is the Director of the Interstitial Lung Disease Clinic. She runs clinical trials focused on a cure for Idiopathic Pulmonary Fibrosis. In addition, her research focuses on phenotypic factors and genetic factors associated with Chronic Obstructive Pulmonary Diseases and Interstitial Lung Diseases.

    Board Certification and Academic Information

    Academic Departments Internal Medicine -Professor
    Academic Divisions Public Health
    Board Certification
    American Board of Internal Medicine (Sub: Pulmonary Disease)
    National Board of Medical Examiners

    Education history

    Fellowship Pulmonary Medicine - University of Utah School of Medicine Fellow
    Residency Internal Medicine - Barnes Hospital Resident
    Internship Internal Medicine - Barnes Hospital Intern
    Professional Medical Medicine - Washington University M.D.
    Undergraduate Northwestern University B.S.

    Selected Publications

    Journal Article

    1. Williamson J, Kelley K, Scholand MB, Crossno C, Hummert S, Jeppson P, Jacobson H, Buys S (2025). Efficacy of a novel interstitial lung disease monitoring program in breast cancer patients undergoing treatment with trastuzumab-deruxtecan. Breast Cancer Res Treat, 210(2), 487-491. (Read full article)
    2. Erlandson KM, Geng LN, Selvaggi CA, Thaweethai T, Chen P, Erdmann NB, Goldman JD, Henrich TJ, Hornig M, Karlson EW, Katz SD, Kim C, Cribbs SK, Laiyemo AO, Letts R, Lin JY, Marathe J, Parthasarathy S, Patterson TF, Taylor BD, Duffy ER, Haack M, Julg B, Maranga G, Hernandez C, Singer NG, Han J, Pemu P, Brim H, Ashktorab H, Charney AW, Wisnivesky J, Lin JJ, Chu HY, Go M, Singh U, Levitan EB, Goepfert PA, Nikolich J, Hsu H, Peluso MJ, Kelly JD, Okumura MJ, Flaherman VJ, Quigley JG, Krishnan JA, Scholand MB, Hess R, Metz TD, Costantine MM, Rouse DJ, Taylor BS, Goldberg MP, Marshall GD, Wood J, Warren D, Horwitz L, Foulkes AS, McComsey GA, RECOVER-Adult Cohort (2024). Differentiation of Prior SARS-CoV-2 Infection and Postacute Sequelae by Standard Clinical Laboratory Measurements in the RECOVER Cohort. Ann Intern Med, 177(9), 1209-1221. (Read full article)
    3. Lancaster L, Cottin V, Ramaswamy M, Wuyts WA, Jenkins RG, Scholand MB, Kreuter M, Valenzuela C, Ryerson CJ, Goldin J, Kim GHJ, Jurek M, Decaris M, Clark A, Turner S, Barnes CN, Achneck HE, Cosgrove GP, Lefebvre A, Flaherty KR, PLN-74809-IPF-202 Trial Investigators (2024). Bexotegrast in Patients with Idiopathic Pulmonary Fibrosis: The INTEGRIS-IPF Clinical Trial. Am J Respir Crit Care Med, 210(4), 424-434. (Read full article)
    4. Johnson SR, Bernstein EJ, Bolster MB, Chung JH, Danoff SK, George MD, Khanna D, Guyatt G, Mirza RD, Aggarwal R, Allen A Jr, Assassi S, Buckley L, Chami HA, Corwin DS, Dellaripa PF, Domsic RT, Doyle TJ, Falardeau CM, Frech TM, Gibbons FK, Hinchcliff M, Johnson C, Kanne JP, Kim JS, Lim SY, Matson S, McMahan ZH, Merck SJ, Nesbitt K, Scholand MB, Shapiro L, Sharkey CD, Summer R, Varga J, Warrier A, Agarwal SK, Antin-Ozerkis D, Bemiss B, Chowdhary V, Dematte DAmico JE, Hallowell R, Hinze AM, Injean PA, Jiwrajka N, Joerns EK, Lee JS, Makol A, McDermott GC, Natalini JG, Oldham JM, Saygin D, Lakin KS, Singh N, Solomon JJ, Sparks JA, Turgunbaev M, Vaseer S, Turner A, Uhl S, Ivlev I (2024). 2023 American College of Rheumatology (ACR)/American College of Chest Physicians (CHEST) Guideline for the Screening and Monitoring of Interstitial Lung Disease in People with Systemic Autoimmune Rheumatic Diseases. Arthritis Rheumatol, 76(8), 1201-1213. (Read full article)
    5. Johnson SR, Bernstein EJ, Bolster MB, Chung JH, Danoff SK, George MD, Khanna D, Guyatt G, Mirza RD, Aggarwal R, Allen A Jr, Assassi S, Buckley L, Chami HA, Corwin DS, Dellaripa PF, Domsic RT, Doyle TJ, Falardeau CM, Frech TM, Gibbons FK, Hinchcliff M, Johnson C, Kanne JP, Kim JS, Lim SY, Matson S, McMahan ZH, Merck SJ, Nesbitt K, Scholand MB, Shapiro L, Sharkey CD, Summer R, Varga J, Warrier A, Agarwal SK, Antin-Ozerkis D, Bemiss B, Chowdhary V, Dematte DAmico JE, Hallowell R, Hinze AM, Injean PA, Jiwrajka N, Joerns EK, Lee JS, Makol A, McDermott GC, Natalini JG, Oldham JM, Saygin D, Lakin KS, Singh N, Solomon JJ, Sparks JA, Turgunbaev M, Vaseer S, Turner A, Uhl S, Ivlev I (2024). 2023 American College of Rheumatology (ACR)/American College of Chest Physicians (CHEST) Guideline for the Screening and Monitoring of Interstitial Lung Disease in People with Systemic Autoimmune Rheumatic Diseases. Arthritis Care Res (Hoboken), 76(8), 1070-1082. (Read full article)
    6. Johnson SR, Bernstein EJ, Bolster MB, Chung JH, Danoff SK, George MD, Khanna D, Guyatt G, Mirza RD, Aggarwal R, Allen A Jr, Assassi S, Buckley L, Chami HA, Corwin DS, Dellaripa PF, Domsic RT, Doyle TJ, Falardeau CM, Frech TM, Gibbons FK, Hinchcliff M, Johnson C, Kanne JP, Kim JS, Lim SY, Matson S, McMahan ZH, Merck SJ, Nesbitt K, Scholand MB, Shapiro L, Sharkey CD, Summer R, Varga J, Warrier A, Agarwal SK, Antin-Ozerkis D, Bemiss B, Chowdhary V, Dematte DAmico JE, Hallowell R, Hinze AM, Injean PA, Jiwrajka N, Joerns EK, Lee JS, Makol A, McDermott GC, Natalini JG, Oldham JM, Saygin D, Lakin KS, Singh N, Solomon JJ, Sparks JA, Turgunbaev M, Vaseer S, Turner A, Uhl S, Ivlev I (2024). 2023 American College of Rheumatology (ACR)/American College of Chest Physicians (CHEST) Guideline for the Treatment of Interstitial Lung Disease in People with Systemic Autoimmune Rheumatic Diseases. Arthritis Care Res (Hoboken), 76(8), 1051-1069. (Read full article)
    7. Johnson SR, Bernstein EJ, Bolster MB, Chung JH, Danoff SK, George MD, Khanna D, Guyatt G, Mirza RD, Aggarwal R, Allen A Jr, Assassi S, Buckley L, Chami HA, Corwin DS, Dellaripa PF, Domsic RT, Doyle TJ, Falardeau CM, Frech TM, Gibbons FK, Hinchcliff M, Johnson C, Kanne JP, Kim JS, Lim SY, Matson S, McMahan ZH, Merck SJ, Nesbitt K, Scholand MB, Shapiro L, Sharkey CD, Summer R, Varga J, Warrier A, Agarwal SK, Antin-Ozerkis D, Bemiss B, Chowdhary V, Dematte DAmico JE, Hallowell R, Hinze AM, Injean PA, Jiwrajka N, Joerns EK, Lee JS, Makol A, McDermott GC, Natalini JG, Oldham JM, Saygin D, Lakin KS, Singh N, Solomon JJ, Sparks JA, Turgunbaev M, Vaseer S, Turner A, Uhl S, Ivlev I (2024). 2023 American College of Rheumatology (ACR)/American College of Chest Physicians (CHEST) Guideline for the Treatment of Interstitial Lung Disease in People with Systemic Autoimmune Rheumatic Diseases. Arthritis Rheumatol, 76(8), 1182-1200. (Read full article)
    8. Kulkarni T, Criner GJ, Kass DJ, Rosas IO, Scholand MB, Dilling DF, Summer R, Duncan SR (2024). Design of the STRIVE-IPF trial- study of therapeutic plasma exchange, rituximab, and intravenous immunoglobulin for acute exacerbations of idiopathic pulmonary fibrosis. BMC Pulm Med, 24(1), 143. (Read full article)
    9. Kulkarni T, Criner GJ, Kass DJ, Rosas IO, Scholand MB, Dilling DF, Summer R, Duncan SR (2024). Design of the STRIVE-IPF Trial- Study of Therapeutic Plasma Exchange, Rituximab, and Intravenous Immunoglobulin for Acute Exacerbations of Idiopathic Pulmonary Fibrosis. Res Sq. (Read full article)
    10. Lancaster L, Cottin V, Ramaswamy M, Wuyts WA, Jenkins RG, Scholand MB, Kreuter M, Valenzuela C, Ryerson CJ, Goldin J, Kim GHJ, Jurek M, Decaris M, Clark A, Turner SM, Barnes CN, Achneck HE, Cosgrove GP, Lefebvre A, Flaherty KR (2024). Bexotegrast in people with idiopathic pulmonary fibrosis (IPF): a plain language summary of publication of the INTEGRIS-IPF study. Ther Adv Respir Dis, 18, 17534666241287307. (Read full article)
    11. Gayen SK, Baughman RP, Nathan SD, Wells AU, Kouranos V, Alhamad EH, Culver DA, Barney J, Carmoma EM, Cordova FC, Huitema M, Scholand MB, Wijsenbeek M, Ganesh S, Birring SS, Price LC, Wort SJ, Shlobin OA, Gupta R (2023). Pulmonary hemodynamics and transplant-free survival in sarcoidosis-associated pulmonary hypertension: Results from an international registry. Pulm Circ, 13(4), e12297. (Read full article)
    12. Raghu G, Montesi SB, Silver RM, Hossain T, Macrea M, Herman D, Barnes H, Adegunsoye A, Azuma A, Chung L, Gardner GC, Highland KB, Hudson M, Kaner RJ, Kolb M, Scholand MB, Steen V, Thomson CC, Volkmann ER, Wigley FM, Burlile D, Kemper KA, Knight SL, Ghazipura M (2023). Treatment of Systemic Sclerosis-associated Interstitial Lung Disease: Evidence-based Recommendations. An Official American Thoracic Society Clinical Practice Guideline. Am J Respir Crit Care Med. (Read full article)
    13. Solomon JJ, Danoff SK, Woodhead FA, Hurwitz S, Maurer R, Glaspole I, Dellaripa PF, Gooptu B, Vassallo R, Cox PG, Flaherty KR, Adamali HI, Gibbons MA, Troy L, Forrest IA, Lasky JA, Spencer LG, Golden J, Scholand MB, Chaudhuri N, Perrella MA, Lynch DA, Chambers DC, Kolb M, Spino C, Raghu G, Goldberg HJ, Rosas IO, TRAIL1 Network Investigators (2022). Safety, tolerability, and efficacy of pirfenidone in patients with rheumatoid arthritis-associated interstitial lung disease: a randomised, double-blind, placebo-controlled, phase 2 study. Lancet Respir Med, 11(1), 87-96. (Read full article)
    14. Saketkoo LA, Escorpizo R, Varga J, Keen KJ, Fligelstone K, Birring SS, Alexanderson H, Pettersson H, Chaudhry HA, Poole JL, Regardt M, LeSage D, Sarver C, Lanario J, Renzoni E, Scholand MB, Lammi MR, Kowal-Bielecka O, Distler O, Frech T, Shapiro L, Varju C, Volkmann ER, Bernstein EJ, Drent M, Obi ON, Patterson KC, Russell AM, Global Fellowship on Rehabilitation and Exercise in Systemic Sclerosis G-FoRSS (2022). World Health Organization (WHO) International Classification of Functioning, Disability and Health (ICF) Core Set Development for Interstitial Lung Disease. Front Pharmacol, 13, 979788. (Read full article)
    15. Saketkoo LA LA, Jensen K, Nikoletou D, Newton JJ, Rivera FJ, Howie M, Reese RK, Goodman M, Hart PB, Bembry W, Russell A, Lian I, Lammi MR, Scholand Mb MB, Russell Am AM (2022). Sarcoidosis Illuminations on Living During COVID-19: Patient Experiences of Diagnosis, Management, and Survival Before and During the Pandemic. J Patient Exp, 9, 23743735221075556. (Read full article)
    16. Lee J, White E, Freiheit E, Scholand MB, Strek ME, Podolanczuk AJ, Patel NM, Pulmonary Fibrosis Foundation (2022). Cough-specific Quality of Life Predicts Disease Progression Among Patients with Interstitial Lung Disease: Data from the Pulmonary Fibrosis Foundation Patient Registry. Chest. (Read full article)
    17. Gupta R, Baughman RP, Nathan SD, Wells AU, Kouranos V, Alhamad EH, Culver DA, Barney J, Carmona EM, Cordova FC, Huitema M, Scholand MB, Wijsenbeek M, Ganesh S, Birring SS, Price LC, Wort SJ, Shlobin OA (2022). The six-minute walk test in sarcoidosis associated pulmonary hypertension: Results from an international registry. Respir Med, 196, 106801. (Read full article)
    18. Rahaghi FF, Kolaitis NA, Adegunsoye A, de Andrade J, Flaherty KR, Lancaster L, Lee JS, Levine D, Preston IR, Safdar Z, Saggar R, Sahay S, Scholand MB, Shlobin O, Zisman DA, Nathan SD (2022). Screening Strategies for Pulmonary Hypertension in Patients With Interstitial Lung Disease: A Multidisciplinary Delphi Study. Chest, 162, 145-155. (Read full article)
    19. Huitema MP, Post MC, Grutters JC, Wells AU, Kouranos V, Shlobin OA, Nathan SD, Culver DA, Barney J, Gupta R, Carmona E, Alhamad EH, Scholand MB, Wijsenbeek M, Ganesh S, Lower EE, Engel PJ, Baughman RP (2022). Echocardiographic estimate of pulmonary artery pressure in sarcoidosis patients - real world data from a multi-national study. Sarcoidosis Vasc Diffuse Lung Dis, 38(4), e2021032. (Read full article)
    20. Lasky JA, Case A, Unterman A, Kreuter M, Scholand MB, Chaudhary S, Lofaro LR, Johnson M, Huang J, Bhorade SM, Kennedy GC (2021). The Impact of the Envisia Genomic Classifier in the Diagnosis and Management of Patients with Idiopathic Pulmonary Fibrosis. Ann Am Thorac Soc, 19, 916-924. (Read full article)
    21. Pettersson H, Alexanderson H, Poole JL, Varga J, Regardt M, Russell AM, Salam Y, Jensen K, Mansour J, Frech T, Feghali-Bostwick C, Varj C, Baldwin N, Heenan M, Fligelstone K, Holmner M, Lammi MR, Scholand MB, Shapiro L, Volkmann ER, Saketkoo LA (2021). Exercise as a multi-modal disease-modifying medicine in systemic sclerosis: An introduction by The Global Fellowship on Rehabilitation and Exercise in Systemic Sclerosis (G-FoRSS). Best Pract Res Clin Rheumatol, 35, 101695. (Read full article)
    22. Saketkoo LA, Russell AM, Jensen K, Mandizha J, Tavee J, Newton J, Rivera F, Howie M, Reese R, Goodman M, Hart P, Strookappe B, De Vries J, Rosenbach M, Scholand MB, Lammi MR, Elfferich M, Lower E, Baughman RP, Sweiss N, Judson MA, Drent M (2021). Health-Related Quality of Life (HRQoL) in Sarcoidosis: Diagnosis, Management, and Health Outcomes. Diagnostics (Basel), 11(6). (Read full article)
    23. Martinez FJ, Yow E, Flaherty KR, Snyder LD, Durheim MT, Wisniewski SR, Sciurba FC, Raghu G, Brooks MM, Kim DY, Dilling DF, Criner GJ, Kim H, Belloli EA, Nambiar AM, Scholand MB, Anstrom KJ, Noth I, CleanUP-IPF Investigators of the Pulmonary Trials Cooperative (2021). Effect of Antimicrobial Therapy on Respiratory Hospitalization or Death in Adults With Idiopathic Pulmonary Fibrosis: The CleanUP-IPF Randomized Clinical Trial. JAMA, 325(18), 1841-1851. (Read full article)
    24. Maher TM, Costabel U, Glassberg MK, Kondoh Y, Ogura T, Scholand MB, Kardatzke D, Howard M, Olsson J, Neighbors M, Belloni P, Swigris JJ (2021). Phase 2 trial to assess lebrikizumab in patients with idiopathic pulmonary fibrosis. Eur Respir J, 57(2). (Read full article)
    25. Richeldi L, Scholand MB, Lynch DA, Colby TV, Myers JL, Groshong SD, Chung JH, Benzaquen S, Nathan SD, Davis JR, Schmidt SL, Hagmeyer L, Sonetti D, Hetzel J, Criner GJ, Case AH, Ramaswamy M, Calero K, Gauhar UA, Patel NM, Lancaster L, Choi Y, Pankratz DG, Walsh PS, Lofaro LR, Huang J, Bhorade SM, Kennedy GC, Martinez FJ, Raghu G (2020). Utility of a Molecular Classifier as a Complement to High-Resolution Computed Tomography to Identify Usual Interstitial Pneumonia. Am J Respir Crit Care Med, 203(2), 211-220. (Read full article)
    26. Swigris JJ, Andrae DA, Churney T, Johnson N, Scholand MB, White ES, Matsui A, Raimundo K, Evans CJ (2020). Development and Initial Validation Analyses of the Living with Idiopathic Pulmonary Fibrosis Questionnaire. Am J Respir Crit Care Med, 202(12), 1689-1697. (Read full article)
    27. Rahaghi FF, Safdar Z, Brown AW, de Andrade JA, Flaherty KR, Kaner RJ, King CS, Padilla ML, Noth I, Scholand MB, Shifren A, Nathan SD (2020). Expert consensus on the management of adverse events and prescribing practices associated with the treatment of patients taking pirfenidone for idiopathic pulmonary fibrosis: a Delphi consensus study. BMC Pulm Med, 20(1), 191. (Read full article)
    28. Baughman RP, Scholand MB, Rahaghi FF (2020). Clinical phenotyping: role in treatment decisions in sarcoidosis. Eur Respir Rev, 29(155). (Read full article)
    29. Rahaghi FF, Baughman RP, Saketkoo LA, Sweiss NJ, Barney JB, Birring SS, Costabel U, Crouser ED, Drent M, Gerke AK, Grutters JC, Hamzeh NY, Huizar I, Ennis James W 4th, Kalra S, Kullberg S, Li H, Lower EE, Maier LA, Mirsaeidi M, Mller-Quernheim J, Carmona Porquera EM, Samavati L, Valeyre D, Scholand MB (2020). Delphi consensus recommendations for a treatment algorithm in pulmonary sarcoidosis. Eur Respir Rev, 29(155). (Read full article)
    30. Rahaghi FF, Sweiss NJ, Saketkoo LA, Scholand MB, Barney JB, Gerke AK, Lower EE, Mirsaeidi M, OHare L, Rumbak MJ, Samavati L, Baughman RP (2020). Management of repository corticotrophin injection therapy for pulmonary sarcoidosis: a Delphi study. Eur Respir Rev, 29(155). (Read full article)
    31. Saketkoo LA, Scholand MB, Lammi MR, Russell AM (2020). Patient-reported outcome measures in systemic sclerosis-related interstitial lung disease for clinical practice and clinical trials. J Scleroderma Relat Disord, 5(2 Suppl), 48-60. (Read full article)
    32. Richeldi L, Fernndez Prez ER, Costabel U, Albera C, Lederer DJ, Flaherty KR, Ettinger N, Perez R, Scholand MB, Goldin J, Peony Yu KH, Neff T, Porter S, Zhong M, Gorina E, Kouchakji E, Raghu G (2019). Pamrevlumab, an anti-connective tissue growth factor therapy, for idiopathic pulmonary fibrosis (PRAISE): a phase 2, randomised, double-blind, placebo-controlled trial. Lancet Respir Med, 8(1), 25-33. (Read full article)
    33. Patel NM, Kulkarni T, Dilling D, Scholand MB, Interstitial and Diffuse Lung Disease Network Steering Committee (2019). Preoperative Evaluation of Patients With Interstitial Lung Disease. Chest, 156(5), 826-833. (Read full article)
    34. Wuyts W, Antin-Ozerkis D, Huggins JT, LaCamera PP, Spagnolo P, Vakov M, Wijsenbeek MS, Polman B, Kirchgaessler KU, Scholand MB (2019). Serious adverse events in patients with idiopathic pulmonary fibrosis in the placebo arms of 6 clinical trials. Respir Med, 150, 120-125. (Read full article)

    Review

    1. Balakrishnan B, Callahan SJ, Cherian SV, Subramanian A, Sarkar S, Bhatt N, Scholand MB (2023). Climate Change for the Pulmonologist: A Focused Review. [Review]. Chest. (Read full article)
    2. Saketkoo LA, Frech T, Varj C, Domsic R, Farrell J, Gordon JK, Mihai C, Sandorfi N, Shapiro L, Poole J, Volkmann ER, Lammi M, McAnally K, Alexanderson H, Pettersson H, Hant F, Kuwana M, Shah AA, Smith V, Hsu V, Kowal-Bielecka O, Assassi S, Cutolo M, Kayser C, Shanmugam VK, Vonk MC, Fligelstone K, Baldwin N, Connolly K, Ronnow A, Toth B, Suave M, Farrington S, Bernstein EJ, Crofford LJ, Czirjk L, Jensen K, Hinchclif M, Hudson M, Lammi MR, Mansour J, Morgan ND, Mendoza F, Nikpour M, Pauling J, Riemekasten G, Russell AM, Scholand MB, Seigart E, Rodriguez-Reyna TS, Hummers L, Walker U, Steen V (2021). A comprehensive framework for navigating patient care in systemic sclerosis: A global response to the need for improving the practice of diagnostic and preventive strategies in SSc. [Review]. Best Pract Res Clin Rheumatol, 35(3), 101707. (Read full article)

    Case Report

    1. Werst D, Scarpato B, Callahan SJ, Scholand MB (2020). A 64-Year-Old Man With Multifocal Infiltrates. Chest, 159(3), e151-e154. (Read full article)

    Letter

    1. Scholand MB, Wells AU (2022). Comment on Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults. [Letter to the editor]. Am J Respir Crit Care Med, 206(10), 1296. (Read full article)
    2. Saketkoo LA, Alexanderson H, Lammi MR, LeSage D, Jensen K, Scholand MB, Volkmann ER, Russell AM (2020). An ode to the primal tonic of dance-congratulating the Life of Breath project. [Letter to the editor]. Lancet Respir Med, 8(12), e90-e91. (Read full article)